What CBD actually is

Most commercial CBD is extracted from hemp. The term “hemp” describes cannabis that meets a legal THC threshold. It does not tell you whether the finished extract is accurately labeled or free of contaminants. A current batch test provides that information.

CBD terms that are often confused

CBD labels and articles use several related words as though they mean the same thing. They do not. Understanding the vocabulary makes it easier to compare products and spot claims that leave out important details.

Where CBD comes from

CBD begins as part of the chemistry of Cannabis sativa. The plant produces cannabinoids in glandular structures called trichomes, which are concentrated on flowers and nearby leaves. In the living plant, much of the material exists as cannabidiolic acid, or CBDA, rather than neutral CBD. Heat and time can remove a carboxyl group from CBDA through a process called decarboxylation. That conversion is one reason growing, drying, extraction and processing conditions matter. Two products can both say “hemp extract” while containing different proportions of CBD, CBDA and other plant compounds.

Hemp is a legal classification, not a promise about quality. In the United States it generally refers to cannabis that stays within the federal limit for delta-9 THC on a dry-weight basis. The definition separates hemp from marijuana in law, but it does not tell you how carefully a crop was grown, whether contaminants were introduced, or how much THC remains in a finished serving. Finished-product testing is therefore more useful to a consumer than the word hemp by itself.

Genetics and cultivation influence the starting material. Plant variety, soil, climate, harvest timing and storage can all change the cannabinoid and terpene profile. Producers then choose which plant material to extract and how to refine it. The resulting ingredient may be a full-spectrum extract, a broad-spectrum extract or CBD isolate. These are compositional categories. They do not rank products from best to worst, and they do not predict how a particular person will respond.

Hemp vs cannabis: what is the actual difference?

Hemp and marijuana are not separate plant species. Both are terms used for plants within Cannabis sativa. The difference most people encounter is legal and chemical: hemp is cannabis that meets a defined limit for delta-9 THC, while marijuana is a common legal and cultural term for cannabis that exceeds that limit. Appearance alone cannot reliably tell you which category a plant belongs to.

Where marijuana fits

“Marijuana” usually refers to cannabis with enough THC to fall outside the legal definition of hemp. It is not the scientific name of a separate species. Laws may use the term differently, and regulated adult-use or medical cannabis programs operate under state-specific rules. This is why a statement such as “CBD comes from cannabis” can be botanically correct while still leaving important legal questions unanswered.

Hemp seed oil is not CBD oil

Hemp seed oil is pressed from seeds and is used as a food or cosmetic ingredient. Seeds do not naturally provide meaningful CBD. CBD oil is made by combining a CBD-rich extract, usually obtained from flowers and other cannabinoid-bearing plant material, with a carrier oil. A product labeled only “hemp oil” may refer to either concept, so the ingredient list and stated CBD milligrams matter.

What the 0.3% threshold does not tell you

A percentage measured in plant material does not automatically describe the amount of THC in one finished serving. Nor does legal hemp status prove that a bottle is accurately labeled, free of contaminants or suitable for someone who undergoes drug testing. The finished batch report should identify CBD, THC and the reporting limits used by the laboratory.

How CBD differs from THC

THC can strongly activate CB1 receptors in the brain and produce intoxication. CBD acts differently at these receptors, so it does not create the same high. It can still have noticeable effects.

Full-spectrum, broad-spectrum and isolate

These terms describe which cannabinoids and plant compounds remain after extraction. They do not measure purity or effectiveness.

How plant material becomes a CBD product

Extraction separates oil-soluble compounds from plant material. Common commercial approaches use carbon dioxide or food-grade ethanol. Each method can produce a high-quality ingredient when the process is controlled well. The name of the solvent is less informative than the producer’s controls, the level of refinement and the final test results. A clean-sounding process does not remove the need to test for residual solvents, pesticides, heavy metals and microbial contamination.

After extraction, producers may filter plant waxes, remove chlorophyll, concentrate cannabinoids or use distillation to refine the mixture. Some formulas undergo additional processing to reduce THC. CBD isolate requires still more purification until CBD makes up nearly all of the cannabinoid material. Broad-spectrum production often begins with a more complex extract and targets THC for removal while retaining selected companion compounds. Full-spectrum production retains a wider range of naturally occurring constituents, including legally permitted trace THC.

The extract is only one part of the bottle. CBD is fat soluble, so oils often use carriers such as medium-chain triglyceride oil. The carrier helps disperse the cannabinoid evenly and makes a small amount easier to measure. Flavoring, botanical extracts and minor cannabinoids may also be included. Their presence changes the formula and can change tolerability, but it does not automatically create a clinically proven benefit. Read the complete ingredient list if you have food sensitivities, allergies or restrictions.

Uniformity matters. If the extract is not mixed consistently, the amount in one serving may differ from another. Stability matters too. Light, oxygen and heat can gradually affect ingredients, which is why amber glass, a secure closure and reasonable storage instructions are useful. Keep the bottle closed, follow the label’s storage directions and do not assume a product remains unchanged indefinitely after opening.

For gummies, CBD is mixed into a food matrix. A gummy can simplify serving because each piece is intended to contain a set amount, but manufacturing still has to distribute the cannabinoid evenly across the batch. Edibles also introduce sweeteners, acids, flavors, pectin or gelatin and other dietary considerations. The best format is the one whose ingredients, measurements and expected timing fit the person using it.

The signaling network CBD may influence

The endocannabinoid system, commonly shortened to ECS, is a signaling network found throughout the body. It helps cells adjust communication in response to changing conditions. Researchers study it in relation to appetite, memory, stress responses, sleep, pain processing, immune activity and other functions. This does not mean the ECS controls each function by itself, or that changing the ECS guarantees a particular wellness outcome.

The three working parts of the ECS

Anandamide and 2-AG are not interchangeable

Anandamide takes its name from the Sanskrit word associated with bliss, but the nickname should not be mistaken for a promise about mood. Anandamide and 2-AG differ in abundance, receptor activity and the enzymes that regulate them. Both participate in short-range cellular signaling, and their effects depend on where and when they are produced.

What CB1 and CB2 receptors do

CB1 receptors are especially common in brain regions involved in movement, memory, appetite and perception. THC can activate CB1 strongly enough to produce intoxication. CBD has much lower affinity for the primary binding site on CB1 and does not activate it in the same way. CB2 receptors are studied extensively in immune and inflammatory signaling, but describing CB2 as only an “immune receptor” is an oversimplification.

How CBD fits into the system

CBD is often described as “supporting the ECS,” but that phrase leaves out important detail. Laboratory and early clinical research suggests CBD may influence cannabinoid receptor signaling indirectly. It is also studied at serotonin 5-HT1A receptors, TRPV channels, adenosine signaling and other molecular targets. The importance of each pathway depends on the concentration, tissue, experimental model and outcome being measured.

Claims that CBD simply raises anandamide by “blocking FAAH” are also too absolute. The relationship seen in cells, animals and humans is more complicated, and not every proposed mechanism has been established at typical retail serving levels. Mechanistic evidence can explain why researchers investigate CBD, but it cannot by itself prove that a product will deliver a clinical benefit.

Absorption, timing and bioavailability

CBD cannot affect the body until some of it reaches circulation and tissues. The proportion that reaches circulation is called bioavailability. It varies because CBD is poorly soluble in water, readily associates with fat and is extensively processed by the liver and intestinal enzymes. This helps explain why milligrams on a label are not the same as milligrams that reach the bloodstream.

When CBD is swallowed in a gummy, capsule or drink, it passes through the digestive system before reaching the circulation. Onset is usually slower than with inhalation, and the amount absorbed can vary with the meal, the formula and the individual. A meal containing fat may increase exposure to CBD, sometimes substantially. That can make effects stronger than expected if a person takes the same serving under different meal conditions.

CBD oil used in the mouth may be swallowed immediately or held briefly before swallowing. Some absorption may occur through tissues in the mouth, while the remainder follows the digestive route. Product instructions and study methods differ, so broad claims that every tincture works within an exact number of minutes are not reliable. A practical approach is to use the same method and similar meal conditions while evaluating a product, then allow enough time before deciding whether to take more.

Inhaled CBD can reach circulation quickly, but vaping introduces a different set of product and respiratory risks. This guide focuses on oils and edibles because their measurement and ingredient lists are easier to evaluate. Topical products are another category. Most are designed for local application to skin and should not be assumed to produce the same systemic exposure as an oral product. Transdermal delivery requires a formula specifically designed and tested to move an ingredient across the skin barrier.

CBD also has a variable half-life, which describes how long the body takes to reduce its concentration. Repeated use can create different exposure from a single serving. Age, liver function, genetics, other medicines and frequency of use can all contribute. This is why copying another person’s serving size is a poor substitute for product-specific guidance and professional advice when medical conditions or prescriptions are involved.

Common reasons people use CBD

People commonly explore CBD for stress, sleep, soreness and general wellness. Research has not established all of these uses. Each finding has to be considered in the context of the CBD formulation, dose, study population and measured outcome.

Explore the evidence, outcome by outcome →

Side effects, interactions and who should be cautious

CBD can cause noticeable side effects and less visible changes, including liver-related effects and drug interactions. Risk can vary with dose, duration, formulation, other substances and individual health.

Check the COA for the batch you are buying

A certificate of analysis (COA) records measured results for a specific batch. Check that the product name, batch number and test date match the product you have.

Five ideas that make CBD easier to understand

CBD beginner FAQ

How this guide was prepared

1. FDA: What You Need to Know About CBD Products
2. NIH/NCCIH: Cannabis and Cannabinoids
3. National Cancer Institute: CBD definition
4. National Academies via NCBI: Endocannabinoids and their signaling systems
5. FDA: CBD in foods, safety risks and drug interactions